PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Allogeneic stem cell transplant - Market size and forecast 2018-2023 Autologous stem cell transplant - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing research activity on cancer stem cell key signaling pathways Availability of stem cell markers in the identification of cancer stem cells Development of first-in-class therapeutics using induced pluripotent stem cells PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Cellerant Therapeutics, Inc. Celularity Inc. Gamida Cell Ltd. Nohla Therapeutics, Inc. Sumitomo Dainippon Pharma Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Allogeneic stem cell transplant - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Allogeneic stem cell transplant - Year-over-year growth 2019-2023 (%) Exhibit 21: Allogeneic stem cell transplants under development Exhibit 22: Autologous stem cell transplant - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Autologous stem cell transplant - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Europe - Year-over-year growth 2019-2023 (%) Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Asia - Year-over-year growth 2019-2023 (%) Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 35: ROW - Year-over-year growth 2019-2023 (%) Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Late-stage cancer stem cell therapy Exhibit 39: Impact of drivers and challenges Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Cellerant Therapeutics Inc. - Vendor overview Exhibit 46: Cellerant Therapeutics Inc. - Key offerings Exhibit 47: Celularity Inc. - Vendor overview Exhibit 48: Celularity Inc. - Key offerings Exhibit 49: Gamida Cell Ltd. - Vendor overview Exhibit 50: Gamida Cell Ltd. - Business segments Exhibit 51: Gamida Cell Ltd. - Key offerings Exhibit 52: Nohla Therapeutics Inc. - Vendor overview Exhibit 53: Nohla Therapeutics Inc. - Key offerings Exhibit 54: Sumitomo Dainippon Pharma Co. Ltd. - Vendor overview Exhibit 55: Sumitomo Dainippon Pharma Co. Ltd. - Business segments Exhibit 56: Sumitomo Dainippon Pharma Co. Ltd. - Organizational developments Exhibit 57: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus Exhibit 58: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings Exhibit 59: Validation techniques employed for market sizing Exhibit 60: Definition of market positioning of vendors

Cellerant Therapeutics, Inc. Celularity Inc. Gamida Cell Ltd. Nohla Therapeutics, Inc. Sumitomo Dainippon Pharma Co. Ltd.